Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...

The PRAC still has another safety review on the go for the GLP-1 class, however ... taking them for signs of emerging or worsening depression. The labels for diabetes therapies Ozempic and ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits ...

"Don’t treat the doctor's office like an assignment. Think of it like BODY MAINTENANCE. You’d do it for your car, right?" ...

Instead of waiting for problems to occur and then treating them, 2025's innovations are all about prevention and early ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

WEIGHT-loss jabs are taking the world by storm, with a staggering half a million of us now using them. The injections have ...

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

Actinogen Medical Limited announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem®/UE2343 once-a-day small molecule in ...